

HORIZON 2020 AND RARE DISEASES UPCOMING OPPORTUNITIES FOR RESEARCH ON RARE DISEASES

INFORMATION SESSION

VALENTINA BOTTARELLI EURORDIS 30th October 2013

WHAT'S IN THIS SESSION

- 1. FP7 and its predecessors: how **past EU research programmes** contributed to RD research
- 2. What do we know about **HORIZON 2020**
- 3. International collaboration on RD research: IRDiRC, an *ad hoc* consortium

"Rare disease research is revealing Nature's secrets, held for millennia, with unexpected benefits"

eurordis.org

William A. Gahl



1. FP7 and its predecessors: how **past EU research programmes** contributed to RD research



ROLE OF EC IN RESEARCH

- \rightarrow Role of European Commission in research :
- 1. Funding agency: competitiveness of EU industry, support in predefined areas
- 2. Preparing and implementing policies
- 3. Bringing down barriers
 - between countries:
 - multinational consortia and teams
 - researchers from any country in the world can participate
 - coordination among national funding programmes
 - between different types of organisations: universities, research centres, SMEs, large companies, etc.
 - between disciplines: increased focus on translational research
- 5. Encourage mobility: Marie Curie fellowships available for researchers and for host institutes
- 6. Supporting common infrastructures

main instrument = Framework Programmes (FP)





FPs & RD RESEARCH

	FP5	FP6	FP7	HORIZON 2020
	(1998-2002)	(2002-2006)	(2007-2013)	(2014-2020)
Budget for the entire Research Framework Programme	14 960 M€	17 500 M€	54 582 M€	70 200 M€
Health Specific Programme	"Improving the quality of life and management of living resources"	"Life sciences, genomics and biotechnology for health"	Health Theme (one of the 10 Themes of the 'Cooperation Programme')	"Health, Demographic Change and Wellbeing" (part of the broader area "Societal challenges")
Budget of the 'Health' programme	2 413 M€	2 514 M€	6 100 M€	7 400 M€
Total budget allocated to RD research	64 M€	230 M€	530 M€	?
n° RD specific funded projects	47	59 also including an ERA-Net project (E-Rare) and one SiS (CAPOIRA)	103	?

FOCUS: was on:

- Europe-wide studies of natural history, pathophysiology and
- development of preventive, diagnostic and therapeutic interventions.

EXPECTED IMPACT: help identifying and mobilising the critical mass of expertise in order to:


- shed light on the course and/or mechanisms of rare diseases, or
- test preventative, diagnostic and/or therapeutic approaches to alleviate the negative impact of the disease on the quality of life of the patients and their families, as appropriate, depending on the level of knowledge concerning the specific (group of) disease(s) under study.



Timeframe for FP7 projects

Projects resulting from FP7 calls operating

Official duration of FP7 2007-2013



TOTAL BUDGET:

n° PROJECTS:

Specific RD area « 2.4.4 » or specific topics RD-related:

Other areas where RD-related projects have been funded:

FP7 AND RD RESEARCH – FIGURES

530 million €

103

260,5 million €

270 million € approx (tbc)



	Specific RD area « 2.4.4 » or specific topics RD-related:	n° projects	total budget (M€)
2007	HEALTH-2007-2.4.4-1: Natural course and patho-physiology of rare diseases	10	29
	HEALTH-2007-2.4.4-2: Research capacity- building in the field of rare diseases	1	1
2009	HEALTH-2009-2.4.4-1: Rare neurological diseases	7	41
	HEALTH-2009-2.4.4-2: Preclinical development of substances with a clear potential as ODs	2	4
2010	HEALTH-2010-2.4.4-1: Clinical development of substances with a clear potential as ODs	6	31
	HEALTH-2010-2.4.4-2: ERA-NET for rare diseases	1	2
2012	HEALTH-2012-2.4.4-1: Preclinical and clinical development of substances with clear potential as ODs	10	57
	HEALTH-2012-2.4.4-2: Observational studies	5	15
	HEALTH-2012-2.4.4-3: Best practice, knowledge sharing in the clinical management of RD	1	2
	HEALTH-2012-2.1.1-1: -omics for RDs	4	38
2013	HEALTH.2013.4.2-3: New methodologies for clinical trials for small population groups	2	6
	HEALTH.2013.1.2-1: Imaging technologies for therapeutic interventions in RD	6	34,5
		55	260,5

HEALTH-2007-2.4.4-1: Natural course and patho-physiology of rare diseases

- → 10 projects selected for funding total budget € 29 million
 - PEMPHIGUS **Pemphigus** From autoimmunity to disease
 - EURO-PADNET The pathophysiology and natural course of patients with Primary Antibody Deficiencies (PAD)
 - CUREHLH European initiative to improve knowledge, treatment and survival of haemophagocytic syndromes in children
 - EURADRENAL Pathophysiology and natural course of autoimmune adrenal failure
 - EUCLYD European Consortium for Lysosomal Disorders
 - EURIPFNET European IPF Network: natural course, pathomechanisms & novel treatments in Idiopathic Pulmonary Fibrosis
 - EUNEFRON- European Network for Orphan Nephropathies



HEALTH-2007-2.4.4-2: Research capacity-building in the field of rare diseases

→ 1 project selected for funding - budget of € 1 million

RD PLATFORM - European Platform of Integrated Information Services for Researchers in the Field of Rare Diseases and Orphan Drugs Supporting Team and Project Building



HEALTH-2009-2.4.4-1: Rare neurological diseases

→ 7 projects selected for funding – total budget € 41 million

- BIO-NMD Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders
- FIGHT-MG Myasthenias, a group of immune mediated neurological diseases: from aetiology to therapy
- Fighting blindness of Usher syndrome: diagnosis, pathogenesis and retinal treatment
- LeukoTreat Therapeutic challenge in Leukodystrophies: Translational and ethical research towards clinical trials
- MEFOPA- European Project on Mendelian forms of Parkinson's Disease



HEALTH-2009-2.4.4-2: Preclinical development of substances with a clear potential as orphan drugs

→ 2 projects selected for funding – total budget € 4 million

PRATH - Preclinical study of recombinant human anti-C5 for the treatment of Atypical Haemolytic Uraemic syndrome

RDVCF - Rod-derived Cone Viability Factor



HEALTH-2010-2.4.4-1: Clinical development of substances with a clear potential as orphan drugs

→ 6 projects selected for funding for a budget of € 31 million

- IMPACTT Immunoglobulin IgY pseudomonas. A clinical trial for cystic fibrosis treatment
- AIPGENE Novel Gene therapy for Acute Intermittent Porphyria
- MABSOT Treatment of Delayed Graft Function post solid organ transplantation
- GENEGRAFT Phase I/II ex vivo gene therapy clinical trial for recessive dystrophic epidermolysis bullosa using skin equivalent grafts genetically corrected with a COL7A1-encoding SIN retroviral vector
- PADDINGTON Pharmacodynamic Approaches to Demonstration of Disease-Modification in Huntington's Disease
- ALPHA-MAN Enzyme Replacement Therapy in alpha-Mannosidosis




HEALTH-2010-2.4.4-2: ERA-NET for rare diseases

→ 1 project selected for funding for a budget of € 2 million

E-RARE 2 - transnational funding of collaborative, multidisciplinary projects on rare diseases - coordination (running until Sept 2014)





HEALTH-2012-2.4.4-1: Preclinical and clinical development of substances with clear potential as ODs

→ 10 projects selected for funding for a budget of ~ € 57 million

- DEVELOPAKURE Clinical Development of Nitisinone for Alkaptonuria
- PREVENTTORP novel preventative intervention for the blinding disease retinopathy of prematurity (ROP)
- FIGHT-HLH First Targeted Therapy to FIGHT Hemophagocytic
 Lymphohistiocytosis (HLH)
- MEUSIX Clinical trial of gene therapy for MPS VI
- EUROFANCOLEN Phase I/II Gene Therapy Trial of Fanconi anemia patients with lentiviral vector carrying the FANCA gene



HEALTH-2012-2.4.4-2: **Observational studies**

→ 5 projects selected for funding for a budget of 15 € million

- BESTCILIA Better Experimental Screening and Treatment for Primary Ciliary Dyskinesia
- OPTIMISTIC Observational Prolonged Trial In Myotonic dystrophy type 1 to Improve QoL-Standards
- CHILD-EU Orphans Unite: chILD better together European Management Platform for Childhood Interstitial Lung Diseases
- DESSCIPHER To decipher the optimal management of systemic sclerosis
- DSD-LIFE Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD)



HEALTH-2012-2.4.4-3: Best practices and knowledge sharing in the clinical management of RDs

→ 1 projects selected for funding – total budget 2 € million

 RARE-BESTPRACTICE - Platform for sharing best practices for clinical management of RDs



HEALTH-2012-2.1.1.1-A. Support for international rare diseases research

SUPPORT IRDiRC - Support for international rare disease research to serve the IRDiRC objectives
 → 2 € million

HEALTH-2012-2.1.1.1-B. Clinical utility of -omics for better diagnosis of rare diseases

- NEUROMICS Integrated European -omics research project for diagnosis & therapy in rare neuromuscular & neurodegenerat. diseases → 12 € million
- EURENOMIS European Consortium for High-Throughput Research in Rare
 ★ 12 € million



HEALTH-2012-2.1.1.1-C. Databases, biobanks and clinical 'bioinformatics' hub for rare diseases

■ RD-CONNECT: An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research → 12 € million



HEALTH.2013.4.2-3: New methodologies for clinical trials for small population groups

→ 2 projects selected for funding for a global budget of € 6 million

- IDEAL Integrated DEsign and AnaLysis of small population group trials (methods of general applicability irrespective of indication by Integrated DEsign and AnaLysis of clinical trials in SPG through a multidisciplinary closely collaborating consortium of researchers from European universities, research institutes and industry) - starting 1.11.2013
- ASTERIX Advances in Small Trials dEsign for Regulatory Innovation and eXcellence (validated innovative statistical design methodologies for cost efficient clinical trials deriving reliable results from trials in small population groups, especially focusing on rare diseases) – started 1.10.2013

HEALTH.2013.1.2-1: Development of imaging technologies for therapeutic interventions in rare diseases

→ 6 projects selected for funding for a total of € 34,5 million

- BIOIMAGE-NMD imaging technology to monitor response to novel therapies in neuromuscular diseases (NMD) using Duchenne muscular dystrophy (DMD) as exemplar disease
- COMMITMENT Combined Molecular Microscopy for Therapy and Personalized Medication in Rare Anaemias Treatments
- MULTISYN novel imaging system for combined simultaneous molecular and functional imaging (PET-MRI/fMRI) for two rare diseases synusipathies: multiple systems atrophy (MSA) and parkinsonism due to mutations in the alpha-synuclein gene (SNCA)



	EXAMPLES of RD research from non RD- specific topics	n° projects	total budget (M€)
2011	HEALTH-2011-1.4.1: Regenerative medicine clinical trials	1	5,2
	HEALTH-2011-1.4.2: Tools, technologies and devices for application in regenerative medicine	2	8,9
	HEALTH.2011.1.4-3: Development and production of new, high-affinity protein scaffolds for therapeutic use	1	5,9
	HEALTH-2011-2.1.1-4: Population genetics studies in cardio metabololics disorders population in EU/AC and EECA	1	3
	HEALTH-2011-2.2.1-1: High impact initiative on human genome	1	3
2012	HEALTH-2012-3.2-2: New methodology for HTA	1	3
2013	HEALTH.2013.0-1: Boosting the translation of FP projects' results into innovative applications for health	1	6
	HEALTH.2013.2.1.1-1: Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes	1	12
	HEALTH.2013.1.4-1. Controlling differentiation and proliferation in human stem cells intended for therapeutic use	1	6

Rare diseases: 2013 call for proposals – other areas (not RD-specific)

HEALTH.2013.0-1: Boosting the translation of FP projects' results into innovative applications for health

 SCOPE-DMD - Consortium for Products across Europe in Duchenne Muscular Dystrophy → 6 € million

HEALTH.2013.2.1.1-1: Functional validation in animal and cellular models of genetic determinants of diseases and ageing processes

 SYBIL - Systems biology for the functional validation of genetic determinants of skeletal diseases → 12 € million

HEALTH.2013.1.4-1. Controlling differentiation and proliferation in human stem cells intended for therapeutic use

REPAIR-HD - Human pluripotent stem cell differentiation, safety and preparation for therapeutic transplantation in Huntington's disease
 → 6 € million



Rare diseases: the trend in 2012 - 2013

- Until 2011 included 66 ongoing projects worth 325 million € EC funding
- In 2012 : **108 million €**
- In 2013 : not all project data has been disclosed
- However, from unofficial information, it appears that in the 2013 calls RD research was worth **above 100 million €** of which the majority (over 60 M€) under not specific RD topics
- More than 200 million € allocated to RD research in 2012 2013 by EC funds



Conclusion:

→ Boosting of RD earmarked funds by EC in 2012 – 2013 : more than 200 € million

Dramatic increase as from 2011 in both RD specific and not specific research (-omics and personalised medicine), where RD projects competed with non RD topics

Response of DG Research, Health Directorate, to IRDiRC engagements



Rare diseases in FP7



A selection of over 100 EU-funded projects from 2007 to 2013

(including DG Sanco programme on Public Health)

http://ec.europa.eu/research/health/pdf/ra re-diseases-how-europe-meetingchallenges_en.pdf

CORDIS (FP7 portal) « find a project » http://cordis.europa.eu/fp7/projects_en.ht <u>ml</u>

Rare diseases

How Europe is meeting the challenges



2. What do we know about **HORIZON 2020**



WHAT IS HORIZON 2020

- → New name for the Framework Programme coming after FP7, running from 2014 to 2020
- → Budget almost **70 billion**
- → Brings together Framework Programme FP7, the Competitiveness and Innovation Programme (CIP) and EU's contribution to the European Institute of Technology (EIT)
 - Stronger focus on innovation and close-to-market activities
- → POLICY : A core part of EUROPE 2020, Innovation and European Research Area:
 - Responding to the economic crisis
 - Addressing people's concerns
 - Strengthening EU global position

EUROPE 2020 is the EU's growth strategy for this decade.
5 objectives by 2020: employment, innovation, education, social inclusion and climate/energy.

→ BUDGET : Budget a core part of EU overall budget for 2014-2020







Focus	Research	Research and Innovation		
Budget	50 billion EUR	70,2 billion EUR		
Programme	FP7 CIP EIT	HORIZON 2020		
Pillars	Cooperation People Capacities Ideas	 → Excellent Science → Competitive Industries → Societal Challenges 		
In which pillar to find « health research »	"Health" part of the Cooperation programme European Research Council part of "Ideas" Marie Curie Actions part of "People"	 "Health, demographic & wellbeing challenge" part of "Societal Challenges " European Research Council Marie Sklodowska Curie Actions Research Infrastructures 		
	Research Infrastructures part of "Capacities"	part of "Excellent Science"		



EXCELLENT SCIENCE

24 598 M€

→ Excellent Science

WHY? to attract and retain research talent and provide access to researchers to best infrastructures

1. European Research Council

Frontier research for best individual teams

2. Marie Sklodowska Curie Actions (MSCA)

 Opportunities for training and career development

3. Research infrastructures

Securing access to world-class facilities

13 000 M€

5 700 M€

2 500 M€




COMPETITIVE INDUSTRIES

17 938 M€

\rightarrow Competitive Industries

WHY? to underpin innovation across existing and merging sectors, attract more private investments and support innovative SMEs

- 1. Key Enabling Technologies
 - ICT, nanotechnologies, biotechnology, materials, etc.
- 2. Access to risk finance
 - Leveraging private finance and venture capital for research and innovation
- 3. Innovation in SMEs
 - Fostering innovation in all types of SMEs
 - (extra budget 15% from Societal Challenges)





SOCIETAL CHALLENGES

→ Societal Challenges

27 000 M€

WHY? To face concerns of citizens and society and implement EU policy objectives that need innovation.

HOW?

- multidisciplinary collaborations including social science and humanities
- Promising solutions to be tested demonstrated and scaled up
- 1. Health
- 2. Bio-economy
- 3. Energy
- 4. Transport
- 5. Climate action
- 6. Integrative, innovative societies
- 7. Secure societies

- Brings together FP7 Health and ICT in Health
- Builds on eHealth, ICT & Aging, AAL (ambient assisted living)

7 400 M€



HEALTH PROGRAMME

CROSS-DISEASE THEMES !

- Understanding health, wellbeing and disease
- Preventing disease
- Treating and managing disease
- Active aging and self management of health
- Methods and data
- Health care provision and integrated care
- \rightarrow Change in Horizon 2020 Health Programme :
- NO LONGER Disease Specific topics = NO LONGER RARE DISEASE specific topics (with exceptions)
- Cross-disease THEMES = RD specific project competing with all other diseases



HEALTH PROGRAMME


- \rightarrow In practice :
- HEALTH Specific Programme under the pillar "Societal Challenges"
- → Each Specific Programme will rely on
 - Strategic Programmes (3-year duration) and
 - Work Programmes (2-year duration)





Proposed Work Programme Cycle

2014	2015	2016	2017	2018	2019		2020	
Strategic Program	me							
Work Programme (plus tentative 2016)	1 informa <mark>t</mark> ion for	Strategic Program	ime					
		Work Programme (plus tentative 2018)	2 information for	Strategic Program	nme			
				Work Programme (plus tentative 2020)		for		
							Work F 4	Programme
HEALTH Specific Programme								
				eı	ırordis.org			



Name: Horizon 2020 Advisory group for Health, demographic, change and wellbeing (E02942)

Individual expert appointed in his/her personal capacity-

Name	Nationality	Professional Title
Adrian Saftoiu	Romania	
Anders Olauson	Sweden	
Andriana Prentza	Greece	
David Norris	United Kingdom	
<u>Elias Mossialos</u>	Greece	
Elisabete Weiderpass	Sweden	
Ellen Fritsche	Germany	
<u>Geneviève Inschauspe</u>	France	
<u>Georges De Moor</u>	Belgium	
Hele Everaus	Estonia	
Jackie Hunter	United Kingdom	
Leszek Kaczmarek	Poland	
Lora Fleming	United States of America	
Lucia Monaco	Italy	
Marie-Paule Kieny	France	-Organisation—
Marta Cascante	Spain	Name of Organi
Martine Piccard	Belgium	Name of Organis
Matej Oresic	Slovenia	School of Public h
Mathieu Simon	France	University of Deb
Orla Sheils	Ireland Swiss Tropic University of	
Paolo Lisboa	Portugal	The BioRobotics I
Paula Marques Alves	Portugal	TILDA - Trinity Co
Peter Saraga	United Kingdom Dublin	
Petra Wilson	United Kingdom University Co	
Rafael Bengoa	Spain University	

HEALTH ADVISORY GROUP

→ Health Advisory Group in the Transparency Registry of the EC

http://ec.europa.eu/transparency/rege xpert/index.cfm?do=groupDetail.group Detail&groupID=2942

- → Independent experts consulted to prepare Work Programmes
- → Scientific and industry experts in their own capacity

organisation				
Name of Organisation	Catego ry	Countries/Areas represented		
School of Public heatlh, University of Debrecen	Academia	Hungary		
<u>Swiss Tropical Institute,</u> <u>University of Basel</u>	Academia	Switzerland		
The BioRobotics Institute	Academia	Italy		
<u>TILDA - Trinity College</u> <u>Dublin</u>	Academia	Ireland		
University Copenhagen	Academia	Denmark		
University of Oslo	Academia	Norway		
	eurordis.org			

HEALTH PROGRAMME COMMITTEE

→ Health Programme Committee ???

- No members' name and organisations published in the Transparency Registry of the EC !
- → Member States' forum to give input to Commission on Work Programmes.
- → Approve the final version of the Work Programmes before calls are published
- → Usually research agencies' representatives, e.g. MRC, INSERM etc.
- \rightarrow Link between the EU and national research systems



TIMELINE

→ HORIZON 2020

- → July 2013 : Overall EU budget, informal agreement 2014-2020 (EP & Council)
- → November 2013 : EP and Council formally adopt EU overall budget
- → November/December 2013: EP and Council formally adopt HORIZON 2020
- → 11 December 2013: adoption of WP and publication of the calls for proposals



TIMELINE

\rightarrow WORK PROGRAMME

- → January 2013: First Strategic Programme
- → February 2013: First meetings of the Horizon 2020 Advisory Groups
- → July 2013: Consultation of with Health Programme Committees (MS)
- → Summer 2013: Draft first Work Programme 2014-2015
- → Autumn 2013: EC inter-service consultation and consultation of the Health Programme Committee (MS)
- → 11 December 2013: Adoption of the Work Programme and publication of the calls for proposals



WP 2014-15 ANTICIPATIONS

Unofficial information ! Possible topics:

- → Health promotion and disease prevention: translating -omics into stratified approaches
- \rightarrow Evaluating screening and prevention programmes
- → New diagnostics tools and technologies: in vitro devices, assays and platforms (2014) & in vivo medical imaging technologies (2015)
- \rightarrow Clinical validation of biomarkers
- \rightarrow New therapies for RD (possibly 2015)
- \rightarrow Tools and technologies for advanced therapies
- \rightarrow Effectiveness of healthcare interventions in pediatric [
- ightarrow Pilots on personalised medicine in health and care sys
- → Self-management of health and disease: citizen engagement empowerment supported by ICT
- → Support to ERNs efficient network modelling & validation
- \rightarrow ERA-NET RD research implementing IRDiRC objectives

Exception to general rule of cross-cutting topics ! IRDiRC engagements

сісті



WP 2014-15 ANTICIPATIONS

How each topic will look like:

- → Simplified, less detailed topic description to allow greater freedom to applicants. Should allow innovative approaches to broaden participation
- \rightarrow Structure of each topic:
 - Specific challenge
 - Scope
 - Extended impact
- → Type of action: usually Collaborative Project or Support Action (100% funding)
- ightarrow Topics divided in the main areas of Health SP
- → Focus on personalised health and care, for sustainability and equity in European health and care systems
- \rightarrow Budget roughly 1 billion EUR



H2020 - SIMPLIFICATION





Funding rates	Research activities MAX 75%	Research activities MAX 100%
		(except for Innovation actions, where a
		70% maximum will apply for profit
		making entities)
	Overhead 20%, 60% or actual	Overhead 25%
Time to grant	12 months average	8 months average
	from submission of proposal	from submission of proposal

- → Moving from several funding rates for different beneficiaries and activities to just two
- → Single flat rate to calculate overheads or «indirect costs»
- → Successful applicants to get working more quickly: reduction of average time to grant by 100 days



H2020 IN PRACTICE

\rightarrow In practice :

- Grants for RESEARCH and INNOVATION
- → Funding of all activities and participants: 100%
- → Minimum 3 participants
- → Main type of activity: Research and Development
- \rightarrow Project types:
- Collaborative projects, from large integrated projects to small targeted research projects



\rightarrow In practice :

- SUPPORT and COORDINATION ACTION
- → Funding of all activities and participants: 100%
- → Minimum 1 participant
- → Main type of activity: Support and coordination activities, e.g. accompanying measures, studies, networking, etc.
- \rightarrow Project types:
- Coordination and Support Actions



H2020 IN PRACTICE

\rightarrow In practice :

- ETHICS & OPEN ACCESS
- → Ethics rules remain unchanged from FP7, notably rules on embryonic stem cells.
 - No funding is granted for research activities in a country where such activity is forbidden
 - All research must comply with ethical principles and relevant national (& EU & international legislation)
- → Stronger emphasis on open access of publication funded by H2020 (to avoid duplication and optimising investment)
 - Open access mandatory for all publications resulting from EU-funded research
 - Costs of publications considered as eligible costs



\rightarrow In practice :

- INTERNATIONAL COOPERATION
- → Crucial to address many Horizon 2020 objectives (e.g. IRDiRC)
- → Principle of general openness: Cross-cutting theme across H2020
- \rightarrow Horizon 2020 shall be open to the association of:
 - acceding countries, candidate countries and potential candidates
 - selected international partner countries that fulfill the relevant criteria (capacity, track record, close economic and geographical links to the Union, etc.)



1. International collaboration on RD research: IRDiRC, an *ad hoc* consortium

http://ec.europa.eu/research/health/medical-research/rarediseases/irdirc_en.html#anch_vid



WHY IRDIRC?

\rightarrow Why an international consortium ?

Research challenges related to rare diseases are too big to be mastered alone

- \rightarrow Huge unmet medical needs for patients across the globe
- \rightarrow Small patient populations
- \rightarrow Scarce and scattered research resources and expertise, etc.

\rightarrow Why working together ?

- \rightarrow Mobilise the necessary critical mass of expertise and resources
- → Avoid overlaps in research allowing for more diseases to be tackled
- \rightarrow Deliver new cures and diagnoses to treat patients world-wide

from the Welcome Address of Ruxandra Draghia Akli , Director of DG Research for Health, at the IRDiRC first Conference Dublin, April 2013




IRDIRC'S OBJECTIVES

\rightarrow IRDiRC vision

2020 goals in RD research

- \rightarrow 200 new therapies
- \rightarrow Means to diagnose most RDs



Objective 2020: 200 new therapies Disclaimer: the numbers do not reflect IRDiRC initiatives only

www.irdirc.org



Europe

European Commission

German Federal Ministry of Education and research

Italian Higher Institute of Health Research

Italian Telethon Foundation

French Association against Myopathies

French National Research Agency

Netherlands Organisation for Health Research and Development

Lysogene (FR)

Prosensa (NL)

Spanish Carlos III Health Institute

UK National Institute for Health Research

Shire (IE)

EURORDIS

<u>Asia</u>

BGI (China) Chinese RD Research Consortium (China)

Australia

© rtguest / Fotolia.com

Western Australian Department of Health

IRDIRC MEMBERS

North America

Canadian Institutes for Health Research (CA)

Genome Canada (CA)

Sanford Research (US)

Mendelian Disorders Genome Centres(US)

National Centre for Translational Therapeutics (US)

National Cancer Institute (US)

National Institute of Neurological Disorders and Stroke (US)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)

National Institute of Child Health and Human Development (US)

National Eye Institute (US)


Office of Rare Diseases (US)

Food and Drug Administration (US) NORD

Genetic Alliance

IRDIRC GOVERNANCE

Patient representatives



HOW DOES IT WORK?



How does it work?

- Identify and define shared strategic goals
- Agree to approach jointly and pool resources
- Let each organisation use its own funding mechanisms/timing
- Agree to share data / standards

Alignment – Flexibility - Commitment


- → Governance just reviewed
- Working on a Policy Paper a framework addressing various aspects of research:
 - Sharing data and samples
 - Common quality standards
 - Interoperability and harmonisation of ontologies and biobanks
 - Rapid release of research results, etc.
- Defining GAP ANALYSIS where international research should focus its attention
 - Defining and counting what members fund or have funded
 - Then identifying gaps



What IRDiRC members fund e.g.

- → Genome Canada: IGNITE project, worth 5 million Can \$, as well as Care 4 Rare & FORGE with the CIHR (Canadian Institutes for Health Research) on gene identification;
- → NIH: National Eye Institute: 75 million \$ in RD related projects (a programme has just been launched on rare eye diseases and molecular therapies for eye diseases);
- → FDA Office for Orphan Product Development: budget for grants worth 14 million \$/year
- → Instituto de Salud Carlos III, Spain: approx. 50 projects funded in the field of RDs
- → Telethon Italia bottom-up calls worth 10.5 MEUR/year, with 38 new grants in the last call. Plus a new type of call for "exploratory projects" (diseases that are not addressed otherwise, inputs form POs)
- European Commission: 530 million EUR and 103 projects funded under FP7 (7 years)
 eurordis.org

IRDIRC TIMELINE



WRAP-UP



TAKE HOME MESSAGES

- → RD research funding in FP7 doubled: 530 M€, with a significant increase in the last 2-3 years
- → Health Specific Programme in H2020 approx. 7000 M€
- → 100% funding rate all beneficiaries all activities, 25% flat rate for overheads
- → RD remain a priority in Health Specific Programme, in line with IRDiRC engagements
- → However no RD-specific topics, only cross-cutting topics (with some exceptions)
- \rightarrow WP 2014-15 calls out on 11th December 2013
- → Next WP: think of contacting your (national) representative at the Health Programme Committee or Health Advisory Group



NATIONAL INFORMATION EVENTS

urordis.org

Austria	21 January 2014	www.era.gv.at
Belgium	15 October 2013	www.ncpwallonie.be
Belgium	14 November 2013	www.h2020-kickoff-belgium.be/
Bulgaria	17 February 2014	coming soon
Croatia	10 February 2014	coming soon
Cyprus	16 January 2014	coming soon
Czech Republic	18 October 2013	www.fp7.cz/cs/conference-teera
Denmark	29 October 2013	http://fivu.dk
Estonia	31 January 2014	www.etag.ee
Finland	11 October 2013	www.tekes.eu
France	16 December 2013	www.horizon2020.gouv.fr
Germany	28-29 January 2014	www.forschungsrahmenprogramm
Greece	10 January 2014	coming soon
Hungary	26-27 November 2013	www.nih.gov.hu/
Ireland	10 December 2013	coming soon
Italy	27 February 2014	coming soon
Latvia	24 January 2014	coming soon
Lithuania	4 December 2013	www.vif2013.com
Luxembourg	14 January 2014	www.innovation.public.lu
Netherlands	12 November 2013	www.agentschapnl.nl
Norway	6 December 2013	coming soon
Poland	7 November 2013	coming soon
Portugal	13 December 2013	coming soon
Romania	3-4 October 2013	Conferinta nationala
Slovakia	21 January 2014	coming soon
Slovenia	29 November 2013	coming soon
Spain	11-12 November 2013	Centro de Congresos Príncipe Felipe
Sweden	29 January 2014	coming soon
Switzerland	14-17 January 2014	www.launch-h2020.ch/
United Kingdom	31 January 2014	coming soon

http://ec.europa.eu/rese arch/horizon2020/index ______en.cfm?pg=h2020events

EU-wide in Brussels: 22 November 2013



USEFUL LINKS

• HORIZON 2020

http://ec.europa.eu/research/horizon2020/index_en.cfm?pg=home

EU research http://ec.europa.eu/research

• EU Health Research

http://ec.europa.eu/research/health/index_en.html

• EU Rare Disease Research

<u>http://ec.europa.eu/research/health/medical-research/rare-diseases/index_en.html</u>

• IRDiRC

http://ec.europa.eu/research/health/medical-research/rarediseases/irdirc_en.html

www.irdirc.org

Information on research programmes and projects
 <u>http://cordis.europa.eu/</u>



THANK YOU

QUESTIONS & ANSWERS



